Most Read Articles
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
4 days ago
Men who undergo flexible cystoscopy, particularly with a longer dwell time, may benefit from intraurethral lidocaine as it provides significant pain reduction, suggest the results of a meta-analysis. Evidence is lacking for other tested interventions.
Pearl Toh, 4 days ago
Getting just under one extra hour of sleep per night can go a long way for the health of college students, who are often sleep-deprived, a study suggests.
3 days ago
While douching is not associated with the risk of ovarian cancer, the combination of talc and commercially available douches contributes to a modest increase in the risk of epithelial ovarian cancer beyond that conferred by talc use alone, as shown in a recent study.

Product Highlight - Keytruda

16 Dec 2016
KEYTRUDA – Pembrolizumab 100 mg/4 mL soln for inj – Merck Sharp & Dohme
  • Efficient: Significant efficacy and durable response. 41% ORR whose tumors expressed ≥50% PD-L1 and 84% of patients OR had ongoing responses1,2
  • Predictive: In NSCLC, testing for PD-L1 expression helps to identify patients most likely to respond and to develop a patient’s treatment algorithm1
  • Practical: Convenience dosing of 2 mg/kg administered as an intravenous infusion over 30 minutes every 3 weeks3
  • Manageable Safety Profile: Most of the common adverse reactions were grade 1 or 24
  • PD-1 Blockade: Selectively targets PD-1 directly on the T-cell for the complete PD-1 pathway blockade of both PD-L1 and PD-L2 ligands4

References:
1. Supplement to: Garon EB et.al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl JMed. 2015; 372: 2018-2028
2. Garon EB et.al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl JMed. 2015; 372: 2018-2028
3. Keytruda pack insert LPC-MK 3475-IV-122015
4. Herbst RS et.al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small cell lung cancer (KEYNOTE-010): a randomized controlled trial. Lancet. 2016; 387 (10027): 1540-1550


Further and safety information is available in section 9d, New In This Issue and mims.com.
Full prescribing information is available upon request.
ONCO-1199329-0000 10/16

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
4 days ago
Men who undergo flexible cystoscopy, particularly with a longer dwell time, may benefit from intraurethral lidocaine as it provides significant pain reduction, suggest the results of a meta-analysis. Evidence is lacking for other tested interventions.
Pearl Toh, 4 days ago
Getting just under one extra hour of sleep per night can go a long way for the health of college students, who are often sleep-deprived, a study suggests.
3 days ago
While douching is not associated with the risk of ovarian cancer, the combination of talc and commercially available douches contributes to a modest increase in the risk of epithelial ovarian cancer beyond that conferred by talc use alone, as shown in a recent study.